A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder

被引:58
作者
Nierenberg, Andrew A. [1 ]
Ostacher, Michael J. [1 ]
Huffman, Jeffrey C. [1 ]
Ametrano, Rebecca M. [1 ]
Fava, Maurizio [1 ]
Perlis, Roy H. [1 ]
机构
[1] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Dept Psychiat, Boston, MA 02114 USA
关键词
D O I
10.1097/JOM.0b013e31816b5034
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Antidepressants treat major depressive disorder (AMD) with burden of associated side effects and difficulties with compliance The purpose of this article is to review the efficacy and effectiveness of antidepressants for MDD. Methods: The authors conducted a focused review of selected key issues and references relevant to the clinically relevant pharmacologic treatment of MDD. Principles of treatment are reviewed. Antidepressants reviewed include SSRIs, mixed norepinephrine or serotonin uptake inhibitors, dopamine or norepinephrine uptake inhibitors, norepinephrine uptake inhibitors, antidepressants with mixed properties, and monoamine oxidase inhibitors. Augmentation and psychotherapy strategies are reviewed. Results: Antidepressant efficacy has been established in randomized clinical trials and effectiveness studies for acute and long-term treatment, but many patients do not achieve remission. Augmentation strategies and focused psychotherapy can be helpful. Conclusions: Antidepressants help most patients with MDD but some are resistant to treatment and have a difficult long-term course.
引用
收藏
页码:428 / 436
页数:9
相关论文
共 55 条
  • [1] A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
    Amsterdam, JD
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) : 208 - 214
  • [2] Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
    Brannan, SK
    Mallinckrodt, CH
    Brown, EB
    Wohlreich, MM
    Watkin, JG
    Schatzberg, AF
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (01) : 43 - 53
  • [3] Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Detke, MJ
    Lu, YL
    Goldstein, DJ
    McNamara, RK
    Demitrack, MA
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2002, 36 (06) : 383 - 390
  • [4] Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders
    Fava, GA
    Rafanelli, C
    Cazzaro, M
    Conti, S
    Grandi, S
    [J]. PSYCHOLOGICAL MEDICINE, 1998, 28 (02) : 475 - 480
  • [5] Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression
    Fava, GA
    Rafanelli, C
    Grandi, S
    Canestrari, R
    Morphy, MA
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (10) : 1443 - 1445
  • [6] Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment
    Fava, M
    Judge, R
    Hoog, SL
    Nilsson, ME
    Koke, SC
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) : 863 - 867
  • [7] FAVA M, 1995, J CLIN PSYCHIAT, V56, P52
  • [8] Major depressive subtypes and treatment response
    Fava, M
    Uebelacker, LA
    Alpert, JE
    Nierenberg, AA
    Pava, JA
    Rosenbaum, JF
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (07) : 568 - 576
  • [9] Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
    Fava, M
    Rosenbaum, JF
    Hoog, SL
    Tepner, RG
    Kopp, JB
    Nilsson, ME
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2000, 59 (02) : 119 - 126
  • [10] Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine
    Fava, M
    Mulroy, R
    Alpert, J
    Nierenberg, AA
    Rosenbaum, JF
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (12) : 1760 - 1762